Difference between revisions of "Talazoparib (Talzenna)"
Jump to navigation
Jump to search
m |
m |
||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *10/16/2018: Initial approval | + | *10/16/2018: Initial approval for patients with deleterious or suspected deleterious [[Biomarkers#Germline|germline]] [[Biomarkers#BRCA|BRCA]]-[[Biomarkers#Alterations|mutated]] (gBRCAm), [[Biomarkers#ERBB2|HER2]]-[[Biomarkers#negative|negative]] locally advanced or metastatic [[breast cancer]]. ''(Based on EMBRACA)'' |
==Also known as== | ==Also known as== | ||
| Line 14: | Line 14: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| + | [[Category:Mutation-specific medications]] | ||
[[Category:PARP inhibitors]] | [[Category:PARP inhibitors]] | ||
Revision as of 00:40, 9 May 2021
Mechanism of action
PARP inhibitor
Diseases for which it is used
History of changes in FDA indication
- 10/16/2018: Initial approval for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer. (Based on EMBRACA)
Also known as
- Code name: BMN-673
- Brand name: Talzenna